Votre sélection est vide.
Sélectionnez des ETF pour les comparer les uns aux autres.
Ajoutez un ETF à la sélection en le sélectionnant dans le sélecteur d’ETF ou sous « Comparer » sous le profil de l’ETF.
| Index | MSCI USA Health Care |
| Investment focus | Actions, États-Unis, Santé |
| Fund size | EUR 1 008 m |
| Total expense ratio | 0,12% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Strategy risk | Long-only |
| Sustainability | Non |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in EUR) | 17,45% |
| Inception/ Listing Date | 12 septembre 2017 |
| Distribution policy | Distributing |
| Distribution frequency | Semi annually |
| Fund domicile | Irlande |
| Fund Provider | Xtrackers |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Custodial Services (Ireland) Limited |
| Investment Advisor | DWS Investments UK Limited |
| Custodian Bank | State Street Custodial Services (Ireland) Limited, Dublin 2 |
| Revision Company | Pricewaterhouse Coopers |
| Fiscal Year End | 31 décembre |
| Swiss representative | DWS CH AG |
| Swiss paying agent | Deutsche Bank (Suisse) SA |
| Germany | 30% d’exonération partielle |
| Switzerland | ESTV Reporting |
| Austria | Meldefonds |
| UK | UK Reporting |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | |
| Securities lending | Yes |
| Securities lending counterparty | UBS AG |
| Eli Lilly & Co | 15,04% |
| Johnson & Johnson | 8,46% |
| AbbVie | 6,80% |
| UnitedHealth Group | 5,05% |
| Merck & Co | 4,42% |
| Thermo Fisher Scientific | 3,80% |
| Abbott Laboratories | 3,78% |
| Intuitive Surgical | 3,49% |
| Amgen | 3,14% |
| Gilead Sciences | 2,68% |
| États-Unis | 95,92% |
| Irlande | 2,57% |
| Autre | 1,51% |
| Santé | 98,48% |
| Autre | 1,52% |
| YTD | +1.17% |
| 1 month | -0.19% |
| 3 months | -0.90% |
| 6 months | +12.34% |
| 1 year | -3.74% |
| 3 years | +14.37% |
| 5 years | +48.52% |
| Since inception (MAX) | +115.86% |
| 2025 | +1.00% |
| 2024 | +8.81% |
| 2023 | -1.64% |
| 2022 | +2.98% |
| Rendement actuel de distribution | 1,25% |
| Dividends (last 12 months) | EUR 0,67 |
| Period | Dividend in EUR | Dividend yield in % |
|---|---|---|
| 1 an | EUR 0,67 | 1,19% |
| 2025 | EUR 0,69 | 1,29% |
| 2024 | EUR 0,65 | 1,30% |
| 2023 | EUR 0,61 | 1,19% |
| 2022 | EUR 0,84 | 1,65% |
| Volatility 1 year | 17.45% |
| Volatility 3 years | 14.56% |
| Volatility 5 years | 16.00% |
| Return per risk 1 year | -0.21 |
| Return per risk 3 years | 0.31 |
| Return per risk 5 years | 0.51 |
| Maximum drawdown 1 year | -21.33% |
| Maximum drawdown 3 years | -21.84% |
| Maximum drawdown 5 years | -21.84% |
| Maximum drawdown since inception | -27.86% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | XUHC | - - | - - | - |
| Bourse de Stuttgart | EUR | XUHC | - - | - - | - |
| London Stock Exchange | GBX | XSHC | XSHC LN XUHCEUIV | XSHC.L XUHCEURINAV=SOLA | |
| London Stock Exchange | USD | XUHC | XUHC LN XUHCUSIV | XUHC.L XUHCUSDINAV=SOLA | |
| SIX Swiss Exchange | CHF | XUHC | XUHC SW XSHCGBIV | XUHC.S XSHCINAV=SOLA | |
| SIX Swiss Exchange | USD | XUHC | XSHCGBIV | XSHCINAV=SOLA | |
| XETRA | EUR | XUHC | XUHC GY | XUHC.DE |
| Nom du fonds | Taille du fonds en M € (AuM) | Frais p.a. | Distribution | Réplication |
|---|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 48 | 0,35% p.a. | Distribution | Échantillonnage |